Skip to main content
CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. logo

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. — Investor Relations & Filings

Ticker · 000661 ISIN · CNE0000007J8 LEI · 300300X04OTKZG18WD66 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2024-08-15 Director's Dealing
Country CN China
Listing Shenzhen Stock Exchange 000661

About CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.

https://ccht.jl.cn

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. is a diversified enterprise primarily focused on the research, development, production, and distribution of biopharmaceuticals and healthcare products. The company operates through several key subsidiaries, most notably GeneScience Pharmaceuticals, which specializes in recombinant human growth hormones and pediatric endocrinology treatments. Its product portfolio includes biological drugs, vaccines, and traditional Chinese medicines, targeting therapeutic areas such as growth disorders, infectious diseases, and oncology. The group emphasizes technological innovation and maintains a significant presence in the domestic market while expanding its international footprint. In addition to its core life sciences business, the company maintains interests in real estate development and infrastructure management.

Recent filings

Filing Released Lang Actions
公司董事、监事、高级管理人员增持股份计划公告
Director's Dealing Classification · 95% confidence The document is an announcement regarding a share purchase plan by certain directors, supervisors, and senior management of the company. It details the planned increase in shareholding by these insiders, including amounts, timing, and compliance with regulations. There is no financial report, earnings data, or management discussion of financial results. The content focuses on insider share transactions and plans for share acquisition by company executives. This fits the definition of 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is 1923 characters, which is consistent with a typical insider dealing announcement rather than a full report or regulatory filing. Therefore, the correct classification is DIRS with high confidence.
2024-08-15 Chinese
半年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 95% confidence The document is a summary table detailing non-operating fund occupation and other related party fund transactions for the half-year period of 2024. It includes financial figures such as balances, amounts occupied, interest, and repayments, along with explanations of the nature of the funds and relationships between parties. The document is only 1500 characters long and appears to be a specific financial disclosure related to related party transactions and fund usage rather than a full interim or annual report. It is not a full financial report but a regulatory disclosure of related party fund usage. This type of document fits best under Regulatory Filings (RNS) as it is a compliance disclosure and does not contain comprehensive financial statements or management discussion. Therefore, the classification is RNS with high confidence.
2024-08-15 Chinese
关于2022年限制性股票与股票期权激励计划股票期权注销完成的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the completion of the cancellation of stock options under the 2022 restricted stock and stock option incentive plan. It details board and shareholder meeting approvals, references regulatory compliance, and confirms the completion of the stock option cancellation process. There is no financial data or detailed report content, but rather a formal announcement of a corporate action related to stock options and incentive plans. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about corporate governance and stock option cancellation, not a full report or financial statement.
2024-08-08 Chinese
2024年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2024 third extraordinary shareholders' meeting of Changchun High-tech Industry (Group) Co., Ltd. It includes information about the meeting date, voting methods, attendance, voting results on specific proposals, and legal opinions confirming the validity of the meeting and resolutions. There is no financial data or report content, but rather the official voting results and meeting procedural details. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 2226 characters, which is consistent with a detailed voting results announcement rather than a full report or presentation.
2024-08-05 Chinese
公司章程（2024年8月修订）
Governance Information Classification · 100% confidence The document is a detailed company charter or articles of association (章程) for Changchun High-Tech Industry (Group) Co., Ltd. It includes comprehensive sections on company governance, shareholder rights, board structure, management, financial accounting, and shareholder meetings. It references laws and regulations, outlines the roles and responsibilities of the party committee, shareholders, board of directors, and management, and details procedures for shareholder meetings and voting. This is a governance document that sets out the internal rules and structure of the company rather than a financial report, announcement, or meeting material. It is not an annual report, earnings release, proxy statement, or any other financial filing. Therefore, the appropriate classification is Governance Information (CGR). The document length and detail confirm it is the full governance document, not just an announcement or summary.
2024-08-05 Chinese
关于子公司GenSci098注射液临床试验申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Changchun High & New Technology Industry Group Co., Ltd. regarding the approval of a clinical trial application for a drug by its subsidiary. It contains no financial data, no report or financial statements, and is not a meeting material or voting result. It is an announcement about a regulatory approval related to the company's business operations. The document length is short (1106 characters) and it is clearly an announcement of an event rather than a report or detailed filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or any financial report. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2024-08-05 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.